Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 23 Issue 6, June 2005

Nicotiana benthamiana plants expressing green fluorescent protein (GFP) following transfection with an 'mRNA-like', tobacco mosaic virus-derived expression vector containing the GFP gene (picture taken under UV light). Marillonnet et al. describe the application of this expression vector to recombinant protein production in plants (p 718).

Volume 23 Issue 6

Subscribe

Editorial

Top of page ⤴

News

Top of page ⤴

News in Brief

Top of page ⤴

News

  • Open source biology could provide an answer to innovation-impeding patents.

    • Stephan Herrera
    News
Top of page ⤴

Data Page

Top of page ⤴

News Feature

  • Genetically engineered bacteria made biotech drugs possible. Now, they are becoming drugs in their own right, Monya Baker reports.

    • Monya Baker
    News Feature
Top of page ⤴

Correspondence

Top of page ⤴

Commentary

  • The US Supreme Court is considering the reach of patents into basic research. If it decides to exempt a broad swathe of research, the biotech industry could lose millions.

    • Mauricio A Flores
    • Cathryn Campbell
    Commentary
Top of page ⤴

Investors Lab

Top of page ⤴

Feature

  • Last year, public biotech companies made gains in revenues and profits, but with stock markets lackluster and regulatory issues looming, future growth remains uncertain.

    • Riku Lähteenmäki
    • Stacy Lawrence
    Feature

  • Biotechnology-based businesses have historically looked to venture capitalists for funding. Our recent survey shows that, unlike the public marketplace, where investors' appetite for biotechnology has waxed and waned the last few years, venture capitalists are staying the course.

    • Douglas P Lee
    • Mark D Dibner
    Feature
Top of page ⤴

Patents

Top of page ⤴

News & Views

  • Coupling of localized surface plasmon resonances offers a potential alternative to FRET for measuring nanometer-scale distances.

    • C Shad Thaxton
    • Chad A Mirkin
    News & Views

  • Protamine-antibody fragment fusions enable delivery of siRNAs to specific cells in mice.

    • John J. Rossi
    News & Views

  • The efficient and permanent alteration of a human gene responsible for SCID provides a proof-of-principle demonstration of the potential of zinc-finger nucleases as human therapeutics.

    • Karthikeyan Kandavelou
    • Mala Mani
    • Srinivasan Chandrasegaran
    News & Views
Top of page ⤴

Analysis

Top of page ⤴

Review Article

Top of page ⤴

Article

Top of page ⤴

Letter

Top of page ⤴

New on the Market

Top of page ⤴

Careers and Recruitment

  • Being good at research isn't enough for success in the biotech business. Where do you get the other skills you need?

    • Virginia Gewin
    Careers and Recruitment
Top of page ⤴

People

Top of page ⤴

Search

Advanced search

Quick links